ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-22I2149
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
Global Stroke Prevention in Atrial Fibrillation SPAF Treatment Market Insights and Forecast to 2028
BUY CHAPTERS

Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Research Report 2025

Code: QYRE-Auto-22I2149
Report
August 2025
Pages:72
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Boehringer Ingelheim
Bayer
Johnson & Johnson
Bristol–Myers Squibb
Pfizer Inc
Daiichi Sankyo
Gilead

Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market

Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market

The global market for Stroke Prevention in Atrial Fibrillation (SPAF) Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Atrial fibrillation (AF) now a days has become a common and serious condition affecting almost 1-2% of the total population of age group 65 years and above.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Stroke Prevention in Atrial Fibrillation (SPAF) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Stroke Prevention in Atrial Fibrillation (SPAF) Treatment.
The Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Report

Report Metric Details
Report Name Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market
CAGR 5%
Segment by Type
  • Oral Direct Thrombin Inhibitors
  • Oral Direct Factor Xa Inhibitors
Segment by Application
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Boehringer Ingelheim, Bayer, Johnson & Johnson, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, Gilead
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market report?

Ans: The main players in the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market are Boehringer Ingelheim, Bayer, Johnson & Johnson, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, Gilead

What are the Application segmentation covered in the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market report?

Ans: The Applications covered in the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market report are Hospitals, Clinics, Ambulatory Surgical Centers

What are the Type segmentation covered in the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market report?

Ans: The Types covered in the Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market report are Oral Direct Thrombin Inhibitors, Oral Direct Factor Xa Inhibitors

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Oral Direct Thrombin Inhibitors
1.2.3 Oral Direct Factor Xa Inhibitors
1.3 Market by Application
1.3.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Perspective (2020-2031)
2.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Growth Trends by Region
2.2.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Region (2020-2025)
2.2.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Region (2026-2031)
2.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Dynamics
2.3.1 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Industry Trends
2.3.2 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Drivers
2.3.3 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Challenges
2.3.4 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Revenue
3.1.1 Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Revenue (2020-2025)
3.1.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Players (2020-2025)
3.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue
3.4 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Concentration Ratio
3.4.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue in 2024
3.5 Global Key Players of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Head office and Area Served
3.6 Global Key Players of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment, Product and Application
3.7 Global Key Players of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Breakdown Data by Type
4.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Type (2020-2025)
4.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Type (2026-2031)
5 Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Breakdown Data by Application
5.1 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Historic Market Size by Application (2020-2025)
5.2 Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2020-2031)
6.2 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2020-2025)
6.4 North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2020-2031)
7.2 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2020-2025)
7.4 Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2020-2031)
8.2 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2020-2025)
8.4 Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2020-2031)
9.2 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2020-2025)
9.4 Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (2020-2031)
10.2 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2020-2025)
10.4 Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim
11.1.1 Boehringer Ingelheim Company Details
11.1.2 Boehringer Ingelheim Business Overview
11.1.3 Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.1.4 Boehringer Ingelheim Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
11.1.5 Boehringer Ingelheim Recent Development
11.2 Bayer
11.2.1 Bayer Company Details
11.2.2 Bayer Business Overview
11.2.3 Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.2.4 Bayer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
11.2.5 Bayer Recent Development
11.3 Johnson & Johnson
11.3.1 Johnson & Johnson Company Details
11.3.2 Johnson & Johnson Business Overview
11.3.3 Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.3.4 Johnson & Johnson Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
11.3.5 Johnson & Johnson Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.4.4 Bristol-Myers Squibb Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Details
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.5.4 Pfizer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
11.5.5 Pfizer Recent Development
11.6 Daiichi-Sankyo
11.6.1 Daiichi-Sankyo Company Details
11.6.2 Daiichi-Sankyo Business Overview
11.6.3 Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.6.4 Daiichi-Sankyo Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
11.6.5 Daiichi-Sankyo Recent Development
11.7 Gilead
11.7.1 Gilead Company Details
11.7.2 Gilead Business Overview
11.7.3 Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Introduction
11.7.4 Gilead Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
11.7.5 Gilead Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Boehringer Ingelheim
Bayer
Johnson & Johnson
Bristol–Myers Squibb
Pfizer Inc
Daiichi Sankyo
Gilead
List of Tables
 Table 1. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Oral Direct Thrombin Inhibitors
 Table 3. Key Players of Oral Direct Factor Xa Inhibitors
 Table 4. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Region (2020-2025)
 Table 8. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Region (2026-2031)
 Table 10. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Trends
 Table 11. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Drivers
 Table 12. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Challenges
 Table 13. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Restraints
 Table 14. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Players (2020-2025)
 Table 16. Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment as of 2024)
 Table 17. Ranking of Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment, Headquarters and Area Served
 Table 20. Global Key Players of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment, Product and Application
 Table 21. Global Key Players of Stroke Prevention in Atrial Fibrillation (SPAF) Treatment, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2020-2025)
 Table 25. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Type (2026-2031)
 Table 27. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Application (2020-2025)
 Table 29. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue Market Share by Application (2026-2031)
 Table 31. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Boehringer Ingelheim Company Details
 Table 47. Boehringer Ingelheim Business Overview
 Table 48. Boehringer Ingelheim Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
 Table 49. Boehringer Ingelheim Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025) & (US$ Million)
 Table 50. Boehringer Ingelheim Recent Development
 Table 51. Bayer Company Details
 Table 52. Bayer Business Overview
 Table 53. Bayer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
 Table 54. Bayer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025) & (US$ Million)
 Table 55. Bayer Recent Development
 Table 56. Johnson & Johnson Company Details
 Table 57. Johnson & Johnson Business Overview
 Table 58. Johnson & Johnson Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
 Table 59. Johnson & Johnson Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025) & (US$ Million)
 Table 60. Johnson & Johnson Recent Development
 Table 61. Bristol-Myers Squibb Company Details
 Table 62. Bristol-Myers Squibb Business Overview
 Table 63. Bristol-Myers Squibb Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
 Table 64. Bristol-Myers Squibb Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025) & (US$ Million)
 Table 65. Bristol-Myers Squibb Recent Development
 Table 66. Pfizer Company Details
 Table 67. Pfizer Business Overview
 Table 68. Pfizer Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
 Table 69. Pfizer Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025) & (US$ Million)
 Table 70. Pfizer Recent Development
 Table 71. Daiichi-Sankyo Company Details
 Table 72. Daiichi-Sankyo Business Overview
 Table 73. Daiichi-Sankyo Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
 Table 74. Daiichi-Sankyo Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025) & (US$ Million)
 Table 75. Daiichi-Sankyo Recent Development
 Table 76. Gilead Company Details
 Table 77. Gilead Business Overview
 Table 78. Gilead Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Product
 Table 79. Gilead Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025) & (US$ Million)
 Table 80. Gilead Recent Development
 Table 81. Research Programs/Design for This Report
 Table 82. Key Data Information from Secondary Sources
 Table 83. Key Data Information from Primary Sources
 Table 84. Authors List of This Report


List of Figures
 Figure 1. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Picture
 Figure 2. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Type: 2024 VS 2031
 Figure 4. Oral Direct Thrombin Inhibitors Features
 Figure 5. Oral Direct Factor Xa Inhibitors Features
 Figure 6. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Application: 2024 VS 2031
 Figure 8. Hospitals Case Studies
 Figure 9. Clinics Case Studies
 Figure 10. Ambulatory Surgical Centers Case Studies
 Figure 11. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Report Years Considered
 Figure 12. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Region: 2024 VS 2031
 Figure 15. Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Players in 2024
 Figure 16. Global Top Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment as of 2024)
 Figure 17. The Top 10 and 5 Players Market Share by Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Revenue in 2024
 Figure 18. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Country (2020-2031)
 Figure 20. United States Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Country (2020-2031)
 Figure 24. Germany Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Nordic Countries Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Region (2020-2031)
 Figure 32. China Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Country (2020-2031)
 Figure 40. Mexico Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Share by Country (2020-2031)
 Figure 44. Turkey Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Boehringer Ingelheim Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
 Figure 48. Bayer Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
 Figure 49. Johnson & Johnson Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
 Figure 50. Bristol-Myers Squibb Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
 Figure 51. Pfizer Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
 Figure 52. Daiichi-Sankyo Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
 Figure 53. Gilead Revenue Growth Rate in Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Business (2020-2025)
 Figure 54. Bottom-up and Top-down Approaches for This Report
 Figure 55. Data Triangulation
 Figure 56. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

Stroke Prevention in Atrial Fibrillation Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Heart Devices for Afib Market Research Report 2024
Global Nonvalvular Atrial Fibrillation Drug Market Research Report 2024
Global Bronchial Spasm Treatment Market Research Report 2024
Global Flutriafol Market Research Report 2025
Ventricular Fibrillation Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anticoagulation Therapy Devices Market Research Report 2024
Global Atrial Dilator Market Research Report 2025
Atrial Fibrillation Catheter Radiofrequency Ablation Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Atrial Fibrillation Therapy Device Market Research Report 2024
Global Stroke Treatment Drugs Market Insights Forecast to 2030
Global Bradycardia Devices Market Research Report 2024
Global Stroke Treatment Market Insights Forecast to 2030
Global Anti Fibrotic Therapy for Ocular Fibrosis Market Insights Forecast to 2030
Global Cardiac Pulsed Field Ablation Device Market Research Report 2024
Global Bradycardia Drugs Market Research Report 2024
Global Preventive Treatment of Migraines Market Research Report 2024
Atrial Septal Occlusion Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Muscle Spasm Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antispasmodics Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Low-Density Lipoprotein Cholesterol Assay Kit Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-32E19705
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Cardiovascular Informations (CVIS) Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10A6248
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Pulmonary Arterial Hypertension (PAH) Medicine Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-8I7059
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Heparin Calcium Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-15Y8668
Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions